Samsung's Big Bet on Peptide Therapeutics The recent announcement by Samsung Biologics to acquire PolyPeptide Group for $1.
8 billion has sent shockwaves through the biopharmaceutical industry, highlighting a significant trend in the sector: the growing importance of peptide therapeutics.
This trend is driven by the remarkable efficacy of these short chains of amino acids in treating conditions such as diabetes and obesity.